98%
921
2 minutes
20
Prostate cancer is one of the most prevalent male-specific diseases, where early and accurate diagnosis is essential for effective treatment and preventing disease progression. Assessing disease severity involves analyzing histological tissue samples, which are graded from 1 (healthy) to 5 (severely malignant) based on pathological features. However, traditional manual grading is labor-intensive and prone to variability. This study addresses the challenge of automating prostate cancer classification by proposing a novel histological grade analysis approach. The method integrates the gray-level co-occurrence matrix (GLCM) for extracting texture features with Haar wavelet modification to enhance feature quality. A convolutional neural network (CNN) is then employed for robust classification. The proposed method was evaluated using statistical and performance metrics, achieving an average accuracy of 97.3%, a precision of 98%, and an AUC of 0.95. These results underscore the effectiveness of the approach in accurately categorizing prostate tissue grades. This study demonstrates the potential of automated classification methods to support pathologists, enhance diagnostic precision, and improve clinical outcomes in prostate cancer care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344078 | PMC |
http://dx.doi.org/10.1007/s10278-024-01363-9 | DOI Listing |
BMC Urol
September 2025
Department of Radiology, Osaka Proton Therapy Clinic, 1-27-9 Kasugade naka, Osaka konohana-ku, Osaka, 554-0022, Japan.
Int Urol Nephrol
September 2025
Department of Urology, Brigham and Women's Hospital, Harvard Medical School, 45 Francis St, ASB II-3, Boston, MA, 02115, USA.
Background: With the advancement of MR-based imaging, prostate cancer ablative therapies have seen increased interest to reduce complications of prostate cancer treatment. Although less invasive, they do carry procedural risks, including rectal injury. To date, the medicolegal aspects of ablative therapy remain underexplored.
View Article and Find Full Text PDFBr J Cancer
September 2025
Institute of Life Sciences, Bhubaneswar, Odisha, India.
Background: Docetaxel is the most common chemotherapy regimen for several neoplasms, including advanced OSCC (Oral Squamous Cell Carcinoma). Unfortunately, chemoresistance leads to relapse and adverse disease outcomes.
Methods: We performed CRISPR-based kinome screening to identify potential players of Docetaxel resistance.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, University of California Irvine, Irvine, CA, USA.
Eur Urol Focus
September 2025
Department of Urology, Medical Centre, University of Heidelberg, Heidelberg, Germany; Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany; Department of Urology, Philipps-University Marburg, Marburg, Germany.
Background And Objective: Since 2016, >21 000 patients with prostate cancer (PC) used our personalized online decision aid in routine care in Germany. We analyzed the effects of this online decision aid for men with nonmetastatic PC in a randomized controlled trial.
Methods: In the randomized controlled EvEnt-PCA trial, 116 centers performed 1:1 allocation of 1115 patients with nonmetastatic PC to use an online decision aid (intervention = I) or a printed brochure (control = C).